【摘要】 目前,联合阿司匹林和P2Y12抑制剂的双联抗血小板方案已广泛应用于冠状动脉旁路移植术(CABG)后患者,其中P2Y12抑制剂可以有效增强阿司匹林对血小板聚集的抑制作用,降低阿司匹林抵抗率。但是,双联抗血小板的应用可能会增加出血风险,且有约10%的患者在随访过程中会发生显著心脑血管不良事件,故单纯的抗血小板治疗似乎不能有效防止术后血栓形成。术后应用双联抗血小板方案的治疗时间目前尚未统一。随着新型口服抗凝药的不断进展,未来新型口服抗凝药联合抗血小板治疗可能是改善CABG后患者结局的新方法。更多还原

【Abstract】 At present,dual anti-platelet plan combining aspirin and P2 Y12 inhibitor has been widely used in patients after coronary artery bypass grafting( CABG),and P2 Y12 inhibitor can effectively enhance the inhibition of platelet aggregation of aspirin and reduce the rate of aspirin resistance. However,the application of dual anti-platelet therapy may increase the risk of bleeding,and about 10% of the patients have significant adverse cardiovascular and cerebral events during follow-up,so the anti-platelet treatment alone does not seem to be effective in preventing postoperative thrombosis. The duration of dual anti-platelet plan after surgery has not yet been unified. With the development of new oral anticoagulants,the new oral anticoagulants combined with anti-platelet therapy may improve the postoperative outcome of patients after CABG.更多还原